Skip to main content

Phase 1/2 Rare Disease Deal Benchmarks

Median Upfront
$161M
Range: $70M - $258M
Total Deal Value
$1.1B
Range: $604M - $1.7B
Royalty Rate
6.7% - 13.4%
Tiered up to 17.4%
Dev Milestones
$274M
Range: $150M - $396M

Market Analysis

Phase 1/2 rare disease licensing deals carry a median total deal value of $1.1B, with upfront payments ranging from $70M to $258M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 14% to upfront and 86% to milestones.

The rare disease landscape at the phase 1/2 stage is characterized by limited competitive intensity per indication but growing platform competition. Development milestones average $274M, regulatory milestones contribute $254M, and commercial milestones reach $450M. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths.

Royalty rates for phase 1/2 rare disease deals range from 6.7% to 13.4% at the base tier, with high-tier escalation to 17.4%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1/2 rare disease deals?
Phase 1/2 rare disease deals average $161M in upfront payments, ranging from $70M to $258M. The upfront allocation of 14% of total deal value reflects the clinical stage risk profile.
How are phase 1/2 rare disease deal milestones structured?
Milestones account for approximately 86% of total deal value. Development milestones ($274M) represent the largest component, followed by commercial milestones ($450M) and regulatory milestones ($254M).
What royalty rates are typical for phase 1/2 rare disease licensing?
Base royalty rates range from 6.7% to 13.4%, with tiered escalation to 10.7%-17.4% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included